MTOR and cancer: Ultimately, Akt activates the mammalian target of rapamycin mTOR (specifically the mTORC1 complex), regulating the downstream effectors, which are deeply involved in cancer cell proliferation, survival, angiogenesis and drug resistance [199,200,201,202,203].